Author:
Rini Brian I,Stenzl Arnulf,Zdrojowy Romauld,Kogan Mikhail,Shkolnik Mikhail,Oudard Stephane,Weikert Steffen,Bracarda Sergio,Crabb Simon J,Bedke Jens,Ludwig Joerg,Maurer Dominik,Mendrzyk Regina,Wagner Claudia,Mahr Andrea,Fritsche Jens,Weinschenk Toni,Walter Steffen,Kirner Alexandra,Singh-Jasuja Harpreet,Reinhardt Carsten,Eisen Tim
Reference23 articles.
1. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy;Fyfe;J Clin Oncol,1995
2. Pazopanib versus sunitinib in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2013
3. Integrated functional genomics approach for the design of patient-individual antitumor vaccines;Weinschenk;Cancer Res,2002
4. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy;Singh-Jasuja;Cancer Immunol Immunother,2004
5. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund’s adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants;Schaed;Clin Cancer Res,2002
Cited by
169 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献